OX40 (TNFRSF4)
OX40 is an accelerator that appears on T cells once they are switched on; pressing it makes them multiply and survive longer. Agonist antibodies against it are in trials, including a phase 3 in head and neck cancer.
Overview
TNFRSF4 (chromosome 1p36.33) encodes OX40, the receptor for OX40 ligand (TNFSF4) and a costimulatory molecule implicated in long-term T-cell immunity (UniProt P43489). OX40 ligation augments CD4 and CD8 T-cell clonal expansion, effector differentiation and survival, and in some cases abrogates the suppressive activity of regulatory T cells (Croft 2009, Immunol Rev). INBRX-106, a hexavalent OX40 agonist antibody, is in a phase 2/3 study with pembrolizumab in first-line PD-L1-high head and neck squamous cell carcinoma (NCT06295731).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · OX40 is an accelerator that appears on T cells once they are switched on; pressing it makes them multiply and survive longer. Agonist antibodies against it are in trials, including a phase 3 in head and neck cancer.
- 1 · What it is
OX40 is an accelerator that appears on T cells once they are switched on; pressing it makes them multiply and survive longer. Agonist antibodies against it are in trials, including a phase 3 in head and neck cancer.
- 2 · What goes wrong in cancer
A TNF-receptor-superfamily costimulator induced on activated T cells; agonists need receptor clustering, which is why hexavalent formats are tried.
- 3 · How drugs use it
No product in this corpus aims at OX40 (TNFRSF4) yet. Because it sits on the outside of the cell, it can be reached from the bloodstream: antibodies flag the cell, ADCs deliver a toxin, radioligands deliver radiation, and CAR-T or bispecifics bring a T cell.
External identifiers
Sources: HGNC HGNC:11918 (approved symbol, name, aliases and cross-references); UniProt P43489 (protein name, function and tissue specificity)
Biology
A TNF-receptor-superfamily costimulator induced on activated T cells; agonists need receptor clustering, which is why hexavalent formats are tried.
- Activated T cells (Croft 2009)
- Head and neck squamous cell carcinoma trial of INBRX-106 (NCT06295731)
Notes
top- Prevalence not recorded: HGNC and UniProt carry no positivity rates.
Latest papers
topQuery for this target: (TITLE:"OX40" OR ABSTRACT:"OX40" OR TITLE:"TNFRSF4" OR ABSTRACT:"TNFRSF4" OR TITLE:"CD134" OR ABSTRACT:"CD134" OR TITLE:"ACT35" OR ABSTRACT:"ACT35" OR TITLE:"TNF receptor superfamily member 4" OR ABSTRACT:"TNF receptor superfamily member 4") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about OX40 (TNFRSF4), not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetCD27
Shares CD137 (4-1BB, TNFRSF9), The cancer-immunity cycle, Checkpoint (two meanings) and the tag checkpoint-map.
- TargetLILRB1 (ILT2)
Shares The cancer-immunity cycle, Checkpoint (two meanings), Pembrolizumab and the tag checkpoint-map.
- TargetLILRB2 (ILT4)
Shares The cancer-immunity cycle, Checkpoint (two meanings), Pembrolizumab and the tag checkpoint-map.
- TargetTDO2
Shares The cancer-immunity cycle, Checkpoint (two meanings) and the tag checkpoint-map.
- TargetCD39 (ENTPD1)
Shares The cancer-immunity cycle, Checkpoint (two meanings) and the tag checkpoint-map.
- TargetHHLA2 (B7-H7)
Shares The cancer-immunity cycle, Checkpoint (two meanings) and the tag checkpoint-map.
- TargetAdenosine A2A receptor (ADORA2A)
Shares The cancer-immunity cycle, Checkpoint (two meanings) and the tag checkpoint-map.
- TargetHLA-E
Shares The cancer-immunity cycle, Checkpoint (two meanings) and the tag checkpoint-map.